DE60203929T2 - Behandlungsverfahren und pharmazeutische zusammensetzung zur notfall-empfängnisverhütung - Google Patents
Behandlungsverfahren und pharmazeutische zusammensetzung zur notfall-empfängnisverhütung Download PDFInfo
- Publication number
- DE60203929T2 DE60203929T2 DE60203929T DE60203929T DE60203929T2 DE 60203929 T2 DE60203929 T2 DE 60203929T2 DE 60203929 T DE60203929 T DE 60203929T DE 60203929 T DE60203929 T DE 60203929T DE 60203929 T2 DE60203929 T2 DE 60203929T2
- Authority
- DE
- Germany
- Prior art keywords
- levonorgestrel
- hours
- pharmaceutical composition
- prevention
- coitus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 11
- 238000000034 method Methods 0.000 title description 6
- 230000002265 prevention Effects 0.000 title description 6
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims description 35
- 229960004400 levonorgestrel Drugs 0.000 claims description 35
- 239000003814 drug Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- -1 flavorings Substances 0.000 claims 1
- 235000013355 food flavoring agent Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 description 22
- 239000003826 tablet Substances 0.000 description 20
- 239000000203 mixture Substances 0.000 description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
- 230000002254 contraceptive effect Effects 0.000 description 10
- 239000003433 contraceptive agent Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 7
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 5
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 5
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 5
- 239000008119 colloidal silica Substances 0.000 description 5
- 229960002568 ethinylestradiol Drugs 0.000 description 5
- 229960001021 lactose monohydrate Drugs 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 3
- 210000003756 cervix mucus Anatomy 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229940038565 levonorgestrel 1.5 mg Drugs 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000004696 endometrium Anatomy 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 239000008384 inner phase Substances 0.000 description 2
- 238000004898 kneading Methods 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000008385 outer phase Substances 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000003760 tallow Substances 0.000 description 2
- ORKBYCQJWQBPFG-WOMZHKBXSA-N (8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 ORKBYCQJWQBPFG-WOMZHKBXSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 206010049872 Breast discomfort Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 230000002513 anti-ovulatory effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 231100000546 inhibition of ovulation Toxicity 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000011599 ovarian follicle development Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000019100 sperm motility Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0105173 | 2001-11-27 | ||
| HU0105173A HU227198B1 (en) | 2001-11-27 | 2001-11-27 | Pharmaceutical composition for emergency contraception containing levonorgestrel |
| PCT/HU2002/000129 WO2003045397A1 (en) | 2001-11-27 | 2002-11-26 | Dosage regimen and pharmaceutical composition for emergency contraception |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60203929D1 DE60203929D1 (de) | 2005-06-02 |
| DE60203929T2 true DE60203929T2 (de) | 2006-01-19 |
Family
ID=89998939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60203929T Expired - Lifetime DE60203929T2 (de) | 2001-11-27 | 2002-11-26 | Behandlungsverfahren und pharmazeutische zusammensetzung zur notfall-empfängnisverhütung |
Country Status (33)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2465907C2 (ru) * | 2006-12-20 | 2012-11-10 | Тева Вимен'С Хелс, Инк. | Распадающиеся в полости рта твердые дозированные формы, содержащие прогестин, и способы получения и применение указанных дозированных форм |
| US20090170823A1 (en) * | 2007-12-20 | 2009-07-02 | Duramed Pharmaceuticals, Inc. | Dosage Regimens and Pharmaceutical Compositions and Packages for Emergency Contraception |
| US8512745B2 (en) | 2008-12-08 | 2013-08-20 | Laboratoire Hra Pharma | Ulipristal acetate tablets |
| EP2365811A1 (en) * | 2008-12-12 | 2011-09-21 | Laboratoire HRA Pharma | A method for contraception |
| WO2010119029A1 (en) | 2009-04-14 | 2010-10-21 | Laboratoire Hra-Pharma | Method for on-demand contraception |
| CN102458386B (zh) | 2009-06-23 | 2016-04-06 | 拜耳知识产权有限责任公司 | 用于紧急避孕的药物组合物 |
| CN101732324B (zh) * | 2009-12-31 | 2011-12-07 | 广州朗圣药业有限公司 | 一种含有左炔诺孕酮的紧急避孕药物组合物及其制备方法 |
| RS54880B1 (sr) | 2011-06-01 | 2016-10-31 | Estetra Sprl | Postupak proizvodnje intermedijarnih proizvoda estetrola |
| ME02585B (me) | 2011-06-01 | 2017-06-20 | Estetra Sprl | Postupak proizvodnje intermedijara estetrola |
| EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
| CA2843951C (en) * | 2011-08-11 | 2019-08-06 | Wout WOUTERS | Use of estetrol as emergency contraceptive |
| SG11201503275RA (en) | 2012-11-22 | 2015-06-29 | Bayer Pharma AG | Use and application regimen of a pharmaceutical composition containing levonorgestrel and a cox inhibitor for on-demand contraception |
| CN105451737B (zh) | 2013-05-23 | 2018-04-10 | 拜耳医药股份有限公司 | 药物组合物及其用途以及所述药物组合物用于按需避孕的施用方法 |
| CN103877058A (zh) * | 2014-03-26 | 2014-06-25 | 邵娜 | 一种左炔诺孕酮片及其制备工艺 |
| EP3701944B1 (en) | 2015-06-18 | 2021-12-08 | Estetra SRL | Orodispersible dosage unit containing an estetrol component |
| MA44206B1 (fr) | 2015-06-18 | 2021-04-30 | Estetra Sprl | Comprimé orodispersible comprenant estetrol |
| CU24523B1 (es) | 2015-06-18 | 2021-06-08 | Estetra Sprl | Unidad de dosificación orodispersable que contiene un componente estetrol |
| LT3310345T (lt) | 2015-06-18 | 2021-06-25 | Estetra Sprl | Burnoje disperguojama tabletė, turinti estetrolio |
| CA3178291A1 (en) | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| EP3781171B1 (en) | 2018-04-19 | 2022-02-09 | Estetra SRL | Compounds and their uses for alleviating menopause-associated symptoms |
| CN110917154A (zh) * | 2019-12-12 | 2020-03-27 | 上海信谊天平药业有限公司 | 一种左炔诺孕酮片的制备方法 |
| TWI893101B (zh) | 2020-04-16 | 2025-08-11 | 比利時商埃斯特拉有限責任公司 | 具有降低之副作用之避孕組成物 |
| WO2022026901A2 (en) * | 2020-07-30 | 2022-02-03 | Acer Therapeutics Inc. | Nk antagonists for contraception |
| CN119523923A (zh) * | 2024-11-21 | 2025-02-28 | 华中药业股份有限公司 | 一种左炔诺孕酮片及其制备方法 |
-
2001
- 2001-11-27 HU HU0105173A patent/HU227198B1/hu unknown
-
2002
- 2002-11-26 DE DE60203929T patent/DE60203929T2/de not_active Expired - Lifetime
- 2002-11-26 EA EA200400731A patent/EA006545B1/ru unknown
- 2002-11-26 UA UA20040504015A patent/UA79942C2/uk unknown
- 2002-11-26 AT AT02783334T patent/ATE293978T1/de active
- 2002-11-26 EP EP02783334A patent/EP1448207B1/en not_active Expired - Lifetime
- 2002-11-26 BR BR0210595-0A patent/BR0210595A/pt not_active Application Discontinuation
- 2002-11-26 GE GE5567A patent/GEP20063882B/en unknown
- 2002-11-26 WO PCT/HU2002/000129 patent/WO2003045397A1/en not_active Ceased
- 2002-11-26 OA OA1200400148A patent/OA12730A/fr unknown
- 2002-11-26 KR KR1020047002069A patent/KR100908161B1/ko not_active Expired - Lifetime
- 2002-11-26 IL IL15939402A patent/IL159394A0/xx unknown
- 2002-11-26 ES ES02783334T patent/ES2239727T3/es not_active Expired - Lifetime
- 2002-11-26 RS YUP-42/04A patent/RS50768B/sr unknown
- 2002-11-26 JP JP2003546899A patent/JP2005516904A/ja not_active Withdrawn
- 2002-11-26 CN CNA028137523A patent/CN1551774A/zh active Pending
- 2002-11-26 SI SI200230132T patent/SI1448207T1/xx unknown
- 2002-11-26 PT PT02783334T patent/PT1448207E/pt unknown
- 2002-11-26 HR HR20040584 patent/HRP20040584B1/xx not_active IP Right Cessation
- 2002-11-26 AU AU2002347401A patent/AU2002347401A1/en not_active Abandoned
- 2002-11-26 CA CA2450359A patent/CA2450359C/en not_active Expired - Lifetime
- 2002-11-26 NZ NZ530056A patent/NZ530056A/en not_active IP Right Cessation
- 2002-11-26 PL PL369520A patent/PL206010B1/pl unknown
- 2002-11-26 AP APAP/P/2004/003046A patent/AP1849A/en active
- 2002-11-26 MX MXPA04005104A patent/MXPA04005104A/es active IP Right Grant
- 2002-11-26 DK DK02783334T patent/DK1448207T3/da active
-
2003
- 2003-12-05 IS IS7065A patent/IS2691B/is unknown
-
2004
- 2004-03-26 TN TNP2004000048A patent/TNSN04048A1/en unknown
- 2004-04-20 NO NO20041607A patent/NO333984B1/no not_active IP Right Cessation
- 2004-04-21 MA MA27643A patent/MA27076A1/fr unknown
- 2004-05-26 ZA ZA2004/04114A patent/ZA200404114B/en unknown
- 2004-06-25 EC EC2004005171A patent/ECSP045171A/es unknown
- 2004-10-05 US US10/495,923 patent/US20050288264A2/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2445491B1 (de) | Pharmazeutische zusammensetzung zur notfallempfängnisverhütung | |
| DE69804918T2 (de) | Sehr niedrigdosiertes orales Kontrazeptiv mit weniger Menstruationsblutungen und verzögerter Wirkung | |
| DE3855606T2 (de) | Verwendung von Melatonin zur Herstellung einer kontrazeptiven Zusammensetzung | |
| DE60119703T2 (de) | Hormonersatztherapie unter verwendung einer kombination von konjugierten oestrogenen und medroxyprogesteron azetat | |
| DE19739916C2 (de) | Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen | |
| DE3856508T2 (de) | Oestrogen und Progestin enthaltende Verhütungspackungen | |
| DE69729956T2 (de) | Orale einstufige empfängnisverhütungsmethode und kombinationspräparat das gestagen und estrogen enthält | |
| CA2450359C (en) | Dosage regimen and pharmaceutical composition for emergency contraception | |
| DE4411585A1 (de) | Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption | |
| EP0799042A1 (de) | Progesteronantagonistisch- und antiöstrogen wirksame verbindungen zur gemeinsamen verwendung für die weibliche kontrazeption | |
| DE19549264A1 (de) | Verfahren und Kit zur Kontrazeption | |
| DE3022337C2 (enExample) | ||
| DE102005034498A1 (de) | Orale Kontrazeption mit Trimegeston | |
| DE4313926A1 (de) | Pharmazeutisches Mehrphasenpräparat zur hormonalen Kontrazeption | |
| DE69721314T2 (de) | Hormonzusammensetzung welche ein östrogenes mittel und ein progestatives mittel enthält | |
| EP0787002B1 (de) | Kompetitive progesteronantagonisten zur bedarfsorientierten weiblichen fertilitätskontrolle | |
| DE69731092T2 (de) | Orales contrazeptivum | |
| DE69724796T2 (de) | Biphasische orale verhuetungsmethode und kit die eine kombination von progestin und eines oestrogens enthalten | |
| WO2014079840A1 (de) | Verwendung und anwendungsregime einer pharmazeutischen zusammensetzung enthaltend levonorgestrel und einen cox-inhibitor zur bedarfsweisen ("on-demand") kontrazeption | |
| DD238921A5 (de) | Verfahren zur herstellung einer kontrazeptiven synergistischen zusammensetzung | |
| DE69827017T2 (de) | Kombinationen von endometrium schonenden gestagenen und endometrium atrophisierenden gestagenen mit estrogenen, bei der oralen empfängnisverhütung | |
| EP1690543A1 (de) | Pharmazeutisches Präparat zur Kontrazeption | |
| DD300071A5 (de) | Zusammensetzung zur Empfängnisverhütung bei Frauen | |
| DE2319850C3 (de) | Abgabepackung für orale Kontrazeptive zur täglichen Verabreichung | |
| DE102008033254B4 (de) | Verfahren zur Herstellung eines einphasischen pharmazeutischen Präparates zur oralen Therapie der Regulierung des Blutdruckes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |